CASE Comprehensive Cancer Center, Cleveland, Ohio;
University of Pittsburgh Cancer Institute, Pittsburgh, Pa
Background: Combretastatin A4 phosphate (CA4P) is the first tubulin-binding vascular-disrupting agent tested in the clinic. Phase I studies demonstrated activity in anaplastic thyroid carcinoma (ATC).
Methods: Patients with metastatic ATC, good performance status, normal electrocardiographic and cardiac function, and no prior therapy for disseminated disease were eligible for study. CA4P at a dose of 45 mg/m2 was administered as a 10-minute intravenous infusion on days 1, 8, and 15 every 28 days (1 cycle).
Savvides PS, Cooney M, Agarwala SS, Wang D, Pagedar N, Johnson F, Bhakta S, Lavertu P, Ortiz J, Remick SC. S070 Phase 2 Study of Combretastatin A4 Phosphate (CA4P) in Patients With Advanced Anaplastic Thyroid Carcinoma (ATC). Arch Otolaryngol Head Neck Surg. 2006;132(8):854. doi:10.1001/archotol.132.8.854-a